Search - tctmd.com

Displaying 61 - 80 of 185

Sort: Relevancy | Date

Presentation TCT 2019

Clinical Outcome at 6 Months Between Paclitaxel-Coated Balloon vs. Sirolimus-Coated Balloon in De Novo Coronary Lesions

Presenter: Sandeep Basavarajaiah

September 27, 2019

Presentation TCT 2019

Absence of Risk of Death After Coronary Paclitaxel-Coated Balloons: Systematic Review and Meta-Analysis of Randomized Trials

Presenter: Bruno Scheller

September 27, 2019

Presentation TCT 2019

Treating Challenging SFA Disease in the Era of Paclitaxel Uncertainty

Presenter: Aravinda Nanjundappa

September 27, 2019

Presentation TCT 2019

Emerging Safety Signals and FDA’s Medical Device Safety Action Plan: Responses to the Late Mortality Signal

Presenter: Rebecca Ward

September 26, 2019

Presentation TCT 2019

Potential Study Designs to Address the Mortality Safety Signal

Presenter: Laura Mauri

September 26, 2019

Presentation TCT 2019

Informed Consent and Impact on Clinical Practice: A Clinician’s Perspective and a Pathway Forward

Presenter: Sahil Parikh

September 26, 2019

Presentation TCT 2019

Drug-Eluting Technologies for SFA Disease: Industry’s Perspective and a Pathway Forward

Presenter: Ian Meredith AM

September 26, 2019

Presentation TCT 2019

Is Paclitaxel-Related Mortality From SFA Drug-Eluting Technologies Biologically Plausible?

Presenter: Elazer Edelman

September 26, 2019

Presentation TCT 2019

Paclitaxel-Coated Devices for SFA Disease: An Independent, Patient-Level Meta-Analysis and Other Emerging Data

Presenter: Krishna Rocha-Singh

September 26, 2019

Presentation TCT 2019

New Insights From Our Meta-Analysis of Paclitaxel-Coated Device Randomized Trials for SFA Disease (And the Response It Has Generated)

Presenter: Konstantinos Katsanos

September 26, 2019

Presentation TCT 2019

1-Year Late Lumen Loss With a Polymer-Coated Paclitaxel-Eluting Stent and a Polymer-Free Paclitaxel-Coated Stent for Femoropopliteal Disease: Study Results

Presenter: Daizo Kawasaki

September 26, 2019

Presentation TCT 2019

Mortality Risk Following Application of Paclitaxel-Coated Devices in Femoropopliteal Lesion: Results From the CAROOT Study

Presenter: Yoshimitsu Soga

September 26, 2019

Presentation TCT 2019

Safety of PTX Devices for PAD in Japan: Academic View

Presenter: Masato Nakamura

September 26, 2019

Presentation TCT 2019

Statistical Considerations: Competing Risk, Pooling Data, RCT vs. Observational Data

Presenter: Roseann White

September 26, 2019

Presentation TCT 2019

Moving From “Signal Detection” to “Signal Discernment”: An FDA View

Presenter: Eleni Whatley

September 26, 2019

Presentation TCT 2019

Current DCBs: Challenges of Paclitaxel and the Downsides of Coatings

Presenter: Robert Byrne

September 26, 2019

Presentation TCT 2019

TCT 62: A polymer-free paclitaxel eluting stent (Zilver® PTX®) versus a bare metal stent (Misago®) for de novo femoropopliteal lesions (BATTLE): a randomised trial

Presenter: Yann Gouëffic

September 25, 2019

Presentation ARCH 2019

Paclitaxel DCB: Back to the Dark Ages for PAD?

Presenter: George S. Chrysant

April 12, 2019

Presentation CIT 2019

New Drug-Coated Balloon Technologies: Limus and Beyond

Presenter: Bruno Scheller

March 28, 2019

Presentation CIT 2019

Could Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal Artery Increase the Risk of Death?

Presenter: Sahil A. Parikh

March 28, 2019

Advertisement

Clinical Outcome at 6 Months Between Paclitaxel-Coated Balloon vs. Sirolimus-Coated Balloon in De Novo Coronary Lesions

Absence of Risk of Death After Coronary Paclitaxel-Coated Balloons: Systematic Review and Meta-Analysis of Randomized Trials

Treating Challenging SFA Disease in the Era of Paclitaxel Uncertainty

Emerging Safety Signals and FDA’s Medical Device Safety Action Plan: Responses to the Late Mortality Signal

Potential Study Designs to Address the Mortality Safety Signal

Informed Consent and Impact on Clinical Practice: A Clinician’s Perspective and a Pathway Forward

Drug-Eluting Technologies for SFA Disease: Industry’s Perspective and a Pathway Forward

Is Paclitaxel-Related Mortality From SFA Drug-Eluting Technologies Biologically Plausible?

Paclitaxel-Coated Devices for SFA Disease: An Independent, Patient-Level Meta-Analysis and Other Emerging Data

New Insights From Our Meta-Analysis of Paclitaxel-Coated Device Randomized Trials for SFA Disease (And the Response It Has Generated)

1-Year Late Lumen Loss With a Polymer-Coated Paclitaxel-Eluting Stent and a Polymer-Free Paclitaxel-Coated Stent for Femoropopliteal Disease: Study Results

Mortality Risk Following Application of Paclitaxel-Coated Devices in Femoropopliteal Lesion: Results From the CAROOT Study

Safety of PTX Devices for PAD in Japan: Academic View

Statistical Considerations: Competing Risk, Pooling Data, RCT vs. Observational Data

Moving From “Signal Detection” to “Signal Discernment”: An FDA View

Current DCBs: Challenges of Paclitaxel and the Downsides of Coatings

TCT 62: A polymer-free paclitaxel eluting stent (Zilver® PTX®) versus a bare metal stent (Misago®) for de novo femoropopliteal lesions (BATTLE): a randomised trial

Paclitaxel DCB: Back to the Dark Ages for PAD?

New Drug-Coated Balloon Technologies: Limus and Beyond

Could Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal Artery Increase the Risk of Death?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content